Velmishi V, Troja E, Tanka M, Bali D, Dervishi E, Tako A
J Osteoporos. 2023; 2023:3254533.
PMID: 38090017
PMC: 10713248.
DOI: 10.1155/2023/3254533.
Roca-Espiau M, Valero-Tena E, Ereno-Ealo M, Giraldo P
Quant Imaging Med Surg. 2022; 12(7):3717-3724.
PMID: 35782234
PMC: 9246758.
DOI: 10.21037/qims-21-1191.
Degnan A, Ho-Fung V, Ahrens-Nicklas R, Barrera C, Serai S, Wang D
Insights Imaging. 2019; 10(1):70.
PMID: 31289964
PMC: 6616606.
DOI: 10.1186/s13244-019-0743-5.
Fedida B, Touraine S, Stirnemann J, Belmatoug N, Laredo J, Petrover D
Eur Radiol. 2015; 25(10):2969-75.
PMID: 25875285
DOI: 10.1007/s00330-015-3715-2.
Simpson W, Hermann G, Balwani M
World J Radiol. 2014; 6(9):657-68.
PMID: 25276309
PMC: 4176783.
DOI: 10.4329/wjr.v6.i9.657.
Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.
Kamath R, Lukina E, Watman N, Dragosky M, Pastores G, Arreguin E
Skeletal Radiol. 2014; 43(10):1353-60.
PMID: 24816856
PMC: 4141971.
DOI: 10.1007/s00256-014-1891-9.
Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study.
Anderson L, Henley W, Wyatt K, Nikolaou V, Waldek S, Hughes D
J Inherit Metab Dis. 2014; 37(6):961-8.
PMID: 24638276
DOI: 10.1007/s10545-014-9693-8.
Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study.
Anderson L, Henley W, Wyatt K, Nikolaou V, Hughes D, Waldek S
J Inherit Metab Dis. 2014; 37(6):953-60.
PMID: 24515873
DOI: 10.1007/s10545-014-9680-0.
Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.
Lukina E, Watman N, Arreguin E, Dragosky M, Iastrebner M, Rosenbaum H
Blood. 2010; 116(20):4095-8.
PMID: 20713962
PMC: 2993616.
DOI: 10.1182/blood-2010-06-293902.
Radiological aspects of Gaucher disease.
Katz R, Booth T, Hargunani R, Wylie P, Holloway B
Skeletal Radiol. 2010; 40(12):1505-13.
PMID: 20658285
DOI: 10.1007/s00256-010-0992-3.
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Lukina E, Watman N, Arreguin E, Banikazemi M, Dragosky M, Iastrebner M
Blood. 2010; 116(6):893-9.
PMID: 20439622
PMC: 2924227.
DOI: 10.1182/blood-2010-03-273151.
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study.
Sims K, Pastores G, Weinreb N, Barranger J, Rosenbloom B, Packman S
Clin Genet. 2008; 73(5):430-40.
PMID: 18312448
PMC: 2440418.
DOI: 10.1111/j.1399-0004.2008.00978.x.
Liver scintigraphy in a patient with Gaucher disease.
Ohta H, Komibuchi T, Takeda H, Taniguchi T, Mihara Y, Nakano T
Ann Nucl Med. 1993; 7(2):115-8.
PMID: 8318347
DOI: 10.1007/BF03164576.
MR imaging in adults with Gaucher disease type I: evaluation of marrow involvement and disease activity.
Hermann G, Shapiro R, Abdelwahab I, Grabowski G
Skeletal Radiol. 1993; 22(4):247-51.
PMID: 8316866
DOI: 10.1007/BF00197668.
Gaucher disease--the orthopaedic aspect. Report of seven cases.
Tauber C, Tauber T
Arch Orthop Trauma Surg. 1995; 114(3):179-82.
PMID: 7619640
DOI: 10.1007/BF00443393.
Bone marrow investigation with technetium-99m microcolloid and magnetic resonance imaging in patients with malignant myelolympho-proliferative diseases.
Widding A, Smolorz J, Franke M, Linden A, Diehl V, Schicha H
Eur J Nucl Med. 1989; 15(5):230-8.
PMID: 2503382
DOI: 10.1007/BF00257539.
Hemorrhage associated with "bone crisis" in Gaucher's disease identified by magnetic resonance imaging.
Horev G, Kornreich L, Hadar H, Katz K
Skeletal Radiol. 1991; 20(7):479-82.
PMID: 1754907
DOI: 10.1007/BF00194240.
Gaucher's disease. Plain radiography, US, CT and MR diagnosis of lungs, bone and liver lesions.
Hainaux B, Christophe C, Hanquinet S, PERLMUTTER N
Pediatr Radiol. 1992; 22(1):78-9.
PMID: 1594320
DOI: 10.1007/BF02011620.